RxDoctor Payments Data

Kristin Murray, PA

Surgical · Brick, NJNPI 1356815682

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,733 of the $2,552 with a category attached, or 67.9%. Axonics, Inc. accounts for 88.7% of it on its own, with 6 other manufacturers making up the rest. 2023 is the largest year on record at $2,285, more than ten times the $90 reported in 2021.

$2,552in general payments, 2019–2025

Across 29 payments — averaging $88.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Medtronic$156
  • Davol Inc.$62
  • AbbVie$30
  • Urovant Sciences Inc$14
  • Astellas Pharma US Inc$14
  • plus $14 from 1 others

What the payments were for

  • Travel & lodging$1,73368%
  • Food & beverage$81932%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,552 in reported general payments places this provider in the 85th percentile of 462 surgical providers in New Jersey.

See all surgical providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,190
Medicare patients
239
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron79$65,698
GemtesaVibegron66$59,808
PremarinEstrogens, Conjugated25$10,606
Estradiol70$4,403
Methenamine Hippurate26$2,109
Trospium Chloride ErTrospium Chloride13$1,844
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst77$779
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$361
Cephalexin17$100
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim36$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$14$65,69879 claims
Sumitomo Pharma America, Inc.Gemtesa$14$59,80866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 462 surgical providers in New Jersey.

Other surgical in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →